Autonomix Receives Uzbekistan Ethics Approval To Launch Proof-of-Concept Human Clinical Study Trial For Cancer Pain Nerve Ablation

Autonomix Medical, Inc., a company developing advanced medical device technologies to target nervous system-related diseases, announced it has received Ethics Committee approval from Uzbekistan’s Ministry of Health to begin a new phase of its clinical trial. This follow-on study, known as PoC 2, builds on earlier success and aims to evaluate the safety and efficacy of its transvascular nerve ablation technology for treating cancer pain. Patient enrollment for this trial is set to begin in June 2025.

“This next phase of our clinical program represents a meaningful advancement for Autonomix. With Ethics Committee approval, we can now expand our evaluation beyond severe pancreatic cancer pain to include a broader range of visceral cancers. The initial phase of our study in late-stage pancreatic cancer patients delivered promising results, demonstrating significant pain reduction, substantial decreases in opioid use, and meaningful improvements in quality of life. These outcomes reinforce our belief that Autonomix’s technology has the potential to address multiple cancer indications with significant unmet need and transform the standard of care. As we build on this momentum, we see a clear opportunity to create long-term value by unlocking a broader set of impactful clinical applications,” said Brad Hauser, CEO of Autonomix.

The follow-up PoC 2 trial stems from encouraging results seen in Autonomix’s initial human study (PoC 1), which targeted patients suffering from severe pain due to pancreatic cancer. The second phase is designed to expand the market potential of the therapy by targeting additional visceral cancers, including those affecting the liver, gall bladder, and bile ducts, as well as earlier-stage pancreatic cancers with moderate to severe pain that involve the Celiac Plexus.

The technology from Autonomix works for many illnesses and therefore has the potential to help a lot of people suffering from conditions like cardiology, pain and hypertension. The PoC 2 trial is being carried out in the context of interventional oncology pain management, yet it will help lead the way to cover various clinical fields in the future.